SIDE AGREEMENTSide Agreement • December 22nd, 2011 • Coronado Biosciences Inc • Pharmaceutical preparations
Reference is made to the (i) Exclusive License Agreement dated December 8, 2005 (the “License Agreement”) by and between the University of Iowa Research Foundation (“UIRF”) and OvaMed GmbH (“OvaMed” or “LICENSEE”), and (ii) exclusive Sublicense Agreement dated December 12, 2005, as amended (the “Sublicense Agreement”) by and between OvaMed and Coronado Biosciences, Inc., as successor to Asphelia Pharmaceuticals, Inc. (“Asphelia”) and Collingwood Pharmaceuticals, Inc. (“Coronado”).
AMENDMENT NO. 1 TO AGREEMENTAgreement • December 22nd, 2011 • Coronado Biosciences Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this “Amendment”), effective as of December 19, 2011 (the “Amendment Effective Date”), is entered into by and between Coronado Biosciences, Inc., a Delaware corporation with an office at 15 New England Executive Park, Burlington, MA 01803 (“Company”), and Bobby W. Sandage, Jr., Ph.D. (the “Executive”). Company and Executive are each sometimes referred to herein as a “Party” and collectively referred to herein as the “Parties”.
TERMS OF AGREEMENTTerms of Agreement • December 22nd, 2011 • Coronado Biosciences Inc • Pharmaceutical preparations
The purposes of this Terms of Agreement, effective as of December 22, 2011 (“Effective Date”) are to (i) set forth the general agreements with respect to a collaboration and associated transactions by and among Coronado Biosciences, Inc., having a principal place of business at 15 New England Executive Park, Burlington, MA 01803, USA (“Coronado”), OvaMed GmbH, having a principal place of business at Kiebitzhörn 31, 22885 Barsbuttel, Germany (“OvaMed”), and Dr. Falk Pharma GmbH, having a principal place of business at Leinenweberstrasse 5, Postfach 6529, 79108, Freiburg, Germany (“Falk”); and (ii) provide the framework for a collaboration agreement to be entered into by and among Coronado, OvaMed and Falk incorporating the agreements set forth in this Terms of Agreement and such other customary terms and conditions consistent with comparable agreements in the industry (the “Collaboration Agreement”). Each of Coronado, OvaMed and Falk may be referred to individually as a “Party” and coll
